Building A New Antibody Discovery Platform With Infinimmune's Wyatt McDonnell, Ph.D.
Why It Matters
By fusing AI with a human‑sample database, Infinimmune shortens antibody development cycles, offering biotech firms a faster, cheaper path to market and reshaping investment dynamics in biologics R&D.
Key Takeaways
- •Infinimmune leverages human tissue database and AI for antibody discovery.
- •Founder Wyatt McDonnell’s background blends single‑cell genomics and computational biology.
- •The company secured a $838 million antibody discovery deal with Merck.
- •Their platform integrates barcode‑enabled antigen mapping with AI‑driven design.
- •AI and multi‑omics data fusion accelerates therapeutic candidate identification.
Summary
In the latest episode of Business of Biotech, Life Science Leader’s Ben Comr sits down with Wyatt McDonnell, Ph.D., co‑founder and CEO of Infinimmune, to discuss the company’s novel antibody discovery platform that combines a vast repository of human blood and tissue samples with advanced artificial‑intelligence algorithms. McDonnell traces his journey from a hands‑on microbiology graduate at Vanderbilt, through a pivotal stint at 10X Genomics, to launching Infinimmune four years ago, highlighting how single‑cell sequencing and computational biology shaped his vision.
Infinimmune’s approach hinges on integrating barcode‑enabled antigen‑mapping workflows with AI‑driven design, enabling rapid pairing of antibody sequences to their target antigens. This multi‑omics strategy, built on a curated human sample database, has already attracted a marquee partnership: a discovery deal with Merck valued at up to $838 million. The platform promises to cut traditional discovery timelines and costs by leveraging high‑throughput data and predictive modeling.
McDonnell recounts key moments that informed the technology, from witnessing the rise of next‑generation sequencing at Vanderbilt to the COVID‑19 pandemic’s spotlight on antibody therapeutics. He notes, “When the pandemic hit, the need for rapid antibody mapping became obvious, and our barcode‑enabled workflow was a natural fit.” The conversation also underscores the cultural influence of 10X’s collaborative environment, which taught him to bridge wet‑lab expertise with software development.
The implications are significant: AI‑augmented antibody discovery could accelerate pipeline development for biotech firms, reduce reliance on costly animal models, and deliver more precise therapeutics to patients faster. For investors, Infinimmune’s Merck deal validates the commercial potential of AI‑centric biologics platforms, signaling a shift toward data‑driven drug discovery across the industry.
Comments
Want to join the conversation?
Loading comments...